Skip to main content

Table 2 Sensitivity analyses of the associations between childhood infections and a later diagnosis of ankylosing spondylitis

From: Childhood hospitalisation with infections and later development of ankylosing spondylitis: a national case-control study

Including only cases matched at an age of 27 years or older

Cases (n = 1757)

Controls (n = 7305)

OR

95 % CI

 All infectionsa

258 (14.7)

964 (13.2)

1.13

0.97–1.32

 Entericb

74 (4.2)

333 (4.6)

0.91

0.70–1.19

 Appendicitis

30 (1.7)

169 (2.3)

0.72

0.49–1.07

 Appendectomy

46 (2.6)

234 (3.2)

0.82

0.59–1.13

 Respiratory tractc

159 (9.0)

529 (7.2)

1.27

1.05–1.54

 Tonsillitis

49 (2.8)

169 (2.3)

1.16

0.83–1.61

 Tonsillectomyd

43 (2.4)

151 (2.1)

1.12

0.79–1.59

 Skin

15 (0.9)

66 (0.9)

0.93

0.53–1.64

 Urogenital tract

6 (0.3)

24 (0.3)

1.02

0.41–2.50

 Other

35 (2.0)

113 (1.5)

1.34

0.91–1.97

Including only cases treated with methotrexate, sulphasalazine, and/or TNFi

Cases (n = 794)

Controls (n = 3288)

OR

95 % CI

 All infectionsa

141 (17.8)

553 (16.8)

1.06

0.86–1.31

 Entericb

40 (5.0)

185 (5.6)

0.87

0.61–1.25

 Appendicitis

12 (1.5)

85 (2.6)

0.58

0.31–1.06

 Appendectomy

20 (2.5)

116 (3.5)

0.71

0.44–1.16

 Respiratory tractc

93 (11.7)

329 (10.0)

1.20

0.93–1.54

 Tonsillitis

34 (4.3)

96 (2.9)

1.48

0.98–2.24

 Tonsillectomyd

27 (3.4)

78 (2.4)

1.42

0.90–2.24

 Skin

12 (1.5)

38 (1.2)

1.37

0.71–2.66

 Urogenital tract

1 (0.1)

16 (0.5)

0.28

0.037–2.10

 Other

14 (1.8)

59 (1.8)

0.991

0.54–1.81

Including only cases matched 2007–2011 and excluding all with immunosuppressive or cytostatic treatment, as well as specific treatment for inflammatory bowel disease, 1 year prior to match

Cases (n = 471)

Controls (n = 1836)

OR

95 % CI

 All infectionsa

96 (20.4)

329 (17.9)

1.16

0.89–1.52

 Entericb

26 (5.5)

102 (5.6)

0.92

0.59–1.45

 Appendicitis

6 (1.3)

38 (2.1)

0.57

0.24–1.36

 Appendectomy

11 (2.3)

48 (2.6)

0.84

0.43–1.63

 Respiratory tractc

63 (13.4)

191 (10.4)

1.33

0.97–1.81

 Tonsillitis

27 (5.7)

67 (3.6)

1.58

0.99–2.53

 Tonsillectomyd

20 (4.2)

54 (2.9)

1.40

0.82–2.38

 Skin

3 (0.6)

21 (1.1)

0.56

0.16–1.90

 Urogenital tract

4 (0.8)

8 (0.4)

2.03

0.61–6.78

 Other

14 (3.0)

45 (2.5)

1.29

0.70–2.40

Prescription of antibiotics 1 year prior to match

131 (27.8)

478 (26.0)

p = 0.446

Excluding inflammatory bowel diseasee

Cases (n = 2307)

Controls (n = 9584)

OR

95 % CI

 All infectionsa

405 (17.6)

1555 (16.2)

1.10

0.97–1.25

 Entericb

108 (4.7)

528 (5.5)

0.84

0.67–1.04

 Appendicitis

35 (1.5)

244 (2.5)

0.59

0.41–0.84

 Appendectomy

56 (2.4)

312 (3.3)

0.74

0.55–0.98

 Respiratory tractc

258 (11.2)

873 (9.1)

1.25

1.08–1.46

 Tonsillitis

87 (3.8)

257 (2.7)

1.37

1.07–1.77

 Tonsillectomyd

78 (3.4)

219 (2.3)

1.42

1.09–1.85

 Skin

23 (1.0)

102 (1.1)

0.94

0.59–1.49

 Urogenital tract

9 (0.4)

40 (0.4)

0.90

0.44–1.86

 Other

53 (2.3)

192 (2.0)

1.18

0.87–1.62

  1. All values are shown as n (%)
  2. Exposure data are based on registered events of an infection in inpatient care before the age of 17 years
  3. aIncluding all infectious foci, but not the procedures appendectomy or tonsillectomy; bincluding appendicitis; cincluding tonsillitis; dalso including adenoidectomy; eexcluding all cases/controls with a diagnosis of ulcerative colitis, Crohns’ disease, or any other non-infectious bowel inflammation (see Additional file 1) up until 2 years after the first AS diagnosis of the index case
  4. CI confidence interval, OR odds ratio, TNFi tumour necrosis factor alfa inhibitors